Financhill
Sell
46

FBT Quote, Financials, Valuation and Earnings

Last price:
$162.39
Seasonality move :
4.08%
Day range:
$160.20 - $162.57
52-week range:
$141.38 - $183.60
Dividend yield:
0.73%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
23.9K
Avg. volume:
18.1K
1-year change:
4.06%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
FBT
First Trust NYSE Arca Biotechnology Index Fund
-- -- -- -- --
FHLC
Fidelity MSCI Health Care Index ETF
-- -- -- -- --
PBE
Invesco Biotechnology & Genome ETF
-- -- -- -- --
PJP
Invesco Pharmaceuticals ETF
-- -- -- -- --
XBI
SPDR S&P Biotech ETF
-- -- -- -- --
XLV
Health Care Select Sector SPDR Fund
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
FBT
First Trust NYSE Arca Biotechnology Index Fund
$161.30 -- -- -- $1.17 0.73% --
FHLC
Fidelity MSCI Health Care Index ETF
$63.70 -- -- -- $0.26 1.6% --
PBE
Invesco Biotechnology & Genome ETF
$64.38 -- -- -- $0.13 0.26% --
PJP
Invesco Pharmaceuticals ETF
$79.78 -- -- -- $0.27 1.21% --
XBI
SPDR S&P Biotech ETF
$83.01 -- -- -- $0.01 0.04% --
XLV
Health Care Select Sector SPDR Fund
$133.93 -- -- -- $0.63 1.79% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
FBT
First Trust NYSE Arca Biotechnology Index Fund
-- 0.751 -- --
FHLC
Fidelity MSCI Health Care Index ETF
-- 0.549 -- --
PBE
Invesco Biotechnology & Genome ETF
-- 0.936 -- --
PJP
Invesco Pharmaceuticals ETF
-- 0.292 -- --
XBI
SPDR S&P Biotech ETF
-- 0.979 -- --
XLV
Health Care Select Sector SPDR Fund
-- 0.443 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
FBT
First Trust NYSE Arca Biotechnology Index Fund
-- -- -- -- -- --
FHLC
Fidelity MSCI Health Care Index ETF
-- -- -- -- -- --
PBE
Invesco Biotechnology & Genome ETF
-- -- -- -- -- --
PJP
Invesco Pharmaceuticals ETF
-- -- -- -- -- --
XBI
SPDR S&P Biotech ETF
-- -- -- -- -- --
XLV
Health Care Select Sector SPDR Fund
-- -- -- -- -- --

First Trust NYSE Arca Biotechnology Index Fund vs. Competitors

  • Which has Higher Returns FBT or FHLC?

    Fidelity MSCI Health Care Index ETF has a net margin of -- compared to First Trust NYSE Arca Biotechnology Index Fund's net margin of --. First Trust NYSE Arca Biotechnology Index Fund's return on equity of -- beat Fidelity MSCI Health Care Index ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- --
    FHLC
    Fidelity MSCI Health Care Index ETF
    -- -- --
  • What do Analysts Say About FBT or FHLC?

    First Trust NYSE Arca Biotechnology Index Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity MSCI Health Care Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust NYSE Arca Biotechnology Index Fund has higher upside potential than Fidelity MSCI Health Care Index ETF, analysts believe First Trust NYSE Arca Biotechnology Index Fund is more attractive than Fidelity MSCI Health Care Index ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    0 0 0
    FHLC
    Fidelity MSCI Health Care Index ETF
    0 0 0
  • Is FBT or FHLC More Risky?

    First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.647, which suggesting that the stock is 35.317% less volatile than S&P 500. In comparison Fidelity MSCI Health Care Index ETF has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.505%.

  • Which is a Better Dividend Stock FBT or FHLC?

    First Trust NYSE Arca Biotechnology Index Fund has a quarterly dividend of $1.17 per share corresponding to a yield of 0.73%. Fidelity MSCI Health Care Index ETF offers a yield of 1.6% to investors and pays a quarterly dividend of $0.26 per share. First Trust NYSE Arca Biotechnology Index Fund pays -- of its earnings as a dividend. Fidelity MSCI Health Care Index ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBT or FHLC?

    First Trust NYSE Arca Biotechnology Index Fund quarterly revenues are --, which are smaller than Fidelity MSCI Health Care Index ETF quarterly revenues of --. First Trust NYSE Arca Biotechnology Index Fund's net income of -- is lower than Fidelity MSCI Health Care Index ETF's net income of --. Notably, First Trust NYSE Arca Biotechnology Index Fund's price-to-earnings ratio is -- while Fidelity MSCI Health Care Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust NYSE Arca Biotechnology Index Fund is -- versus -- for Fidelity MSCI Health Care Index ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- -- --
    FHLC
    Fidelity MSCI Health Care Index ETF
    -- -- -- --
  • Which has Higher Returns FBT or PBE?

    Invesco Biotechnology & Genome ETF has a net margin of -- compared to First Trust NYSE Arca Biotechnology Index Fund's net margin of --. First Trust NYSE Arca Biotechnology Index Fund's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- --
    PBE
    Invesco Biotechnology & Genome ETF
    -- -- --
  • What do Analysts Say About FBT or PBE?

    First Trust NYSE Arca Biotechnology Index Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust NYSE Arca Biotechnology Index Fund has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe First Trust NYSE Arca Biotechnology Index Fund is more attractive than Invesco Biotechnology & Genome ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    0 0 0
    PBE
    Invesco Biotechnology & Genome ETF
    0 0 0
  • Is FBT or PBE More Risky?

    First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.647, which suggesting that the stock is 35.317% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.809, suggesting its less volatile than the S&P 500 by 19.078%.

  • Which is a Better Dividend Stock FBT or PBE?

    First Trust NYSE Arca Biotechnology Index Fund has a quarterly dividend of $1.17 per share corresponding to a yield of 0.73%. Invesco Biotechnology & Genome ETF offers a yield of 0.26% to investors and pays a quarterly dividend of $0.13 per share. First Trust NYSE Arca Biotechnology Index Fund pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBT or PBE?

    First Trust NYSE Arca Biotechnology Index Fund quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. First Trust NYSE Arca Biotechnology Index Fund's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, First Trust NYSE Arca Biotechnology Index Fund's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust NYSE Arca Biotechnology Index Fund is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- -- --
    PBE
    Invesco Biotechnology & Genome ETF
    -- -- -- --
  • Which has Higher Returns FBT or PJP?

    Invesco Pharmaceuticals ETF has a net margin of -- compared to First Trust NYSE Arca Biotechnology Index Fund's net margin of --. First Trust NYSE Arca Biotechnology Index Fund's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- --
    PJP
    Invesco Pharmaceuticals ETF
    -- -- --
  • What do Analysts Say About FBT or PJP?

    First Trust NYSE Arca Biotechnology Index Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust NYSE Arca Biotechnology Index Fund has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe First Trust NYSE Arca Biotechnology Index Fund is more attractive than Invesco Pharmaceuticals ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    0 0 0
    PJP
    Invesco Pharmaceuticals ETF
    0 0 0
  • Is FBT or PJP More Risky?

    First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.647, which suggesting that the stock is 35.317% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.427%.

  • Which is a Better Dividend Stock FBT or PJP?

    First Trust NYSE Arca Biotechnology Index Fund has a quarterly dividend of $1.17 per share corresponding to a yield of 0.73%. Invesco Pharmaceuticals ETF offers a yield of 1.21% to investors and pays a quarterly dividend of $0.27 per share. First Trust NYSE Arca Biotechnology Index Fund pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBT or PJP?

    First Trust NYSE Arca Biotechnology Index Fund quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. First Trust NYSE Arca Biotechnology Index Fund's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, First Trust NYSE Arca Biotechnology Index Fund's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust NYSE Arca Biotechnology Index Fund is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- -- --
    PJP
    Invesco Pharmaceuticals ETF
    -- -- -- --
  • Which has Higher Returns FBT or XBI?

    SPDR S&P Biotech ETF has a net margin of -- compared to First Trust NYSE Arca Biotechnology Index Fund's net margin of --. First Trust NYSE Arca Biotechnology Index Fund's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- --
    XBI
    SPDR S&P Biotech ETF
    -- -- --
  • What do Analysts Say About FBT or XBI?

    First Trust NYSE Arca Biotechnology Index Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust NYSE Arca Biotechnology Index Fund has higher upside potential than SPDR S&P Biotech ETF, analysts believe First Trust NYSE Arca Biotechnology Index Fund is more attractive than SPDR S&P Biotech ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    0 0 0
    XBI
    SPDR S&P Biotech ETF
    0 0 0
  • Is FBT or XBI More Risky?

    First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.647, which suggesting that the stock is 35.317% less volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.063%.

  • Which is a Better Dividend Stock FBT or XBI?

    First Trust NYSE Arca Biotechnology Index Fund has a quarterly dividend of $1.17 per share corresponding to a yield of 0.73%. SPDR S&P Biotech ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.01 per share. First Trust NYSE Arca Biotechnology Index Fund pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBT or XBI?

    First Trust NYSE Arca Biotechnology Index Fund quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. First Trust NYSE Arca Biotechnology Index Fund's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, First Trust NYSE Arca Biotechnology Index Fund's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust NYSE Arca Biotechnology Index Fund is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- -- --
    XBI
    SPDR S&P Biotech ETF
    -- -- -- --
  • Which has Higher Returns FBT or XLV?

    Health Care Select Sector SPDR Fund has a net margin of -- compared to First Trust NYSE Arca Biotechnology Index Fund's net margin of --. First Trust NYSE Arca Biotechnology Index Fund's return on equity of -- beat Health Care Select Sector SPDR Fund's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- --
    XLV
    Health Care Select Sector SPDR Fund
    -- -- --
  • What do Analysts Say About FBT or XLV?

    First Trust NYSE Arca Biotechnology Index Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Health Care Select Sector SPDR Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust NYSE Arca Biotechnology Index Fund has higher upside potential than Health Care Select Sector SPDR Fund, analysts believe First Trust NYSE Arca Biotechnology Index Fund is more attractive than Health Care Select Sector SPDR Fund.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    0 0 0
    XLV
    Health Care Select Sector SPDR Fund
    0 0 0
  • Is FBT or XLV More Risky?

    First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.647, which suggesting that the stock is 35.317% less volatile than S&P 500. In comparison Health Care Select Sector SPDR Fund has a beta of 0.654, suggesting its less volatile than the S&P 500 by 34.588%.

  • Which is a Better Dividend Stock FBT or XLV?

    First Trust NYSE Arca Biotechnology Index Fund has a quarterly dividend of $1.17 per share corresponding to a yield of 0.73%. Health Care Select Sector SPDR Fund offers a yield of 1.79% to investors and pays a quarterly dividend of $0.63 per share. First Trust NYSE Arca Biotechnology Index Fund pays -- of its earnings as a dividend. Health Care Select Sector SPDR Fund pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBT or XLV?

    First Trust NYSE Arca Biotechnology Index Fund quarterly revenues are --, which are smaller than Health Care Select Sector SPDR Fund quarterly revenues of --. First Trust NYSE Arca Biotechnology Index Fund's net income of -- is lower than Health Care Select Sector SPDR Fund's net income of --. Notably, First Trust NYSE Arca Biotechnology Index Fund's price-to-earnings ratio is -- while Health Care Select Sector SPDR Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust NYSE Arca Biotechnology Index Fund is -- versus -- for Health Care Select Sector SPDR Fund. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBT
    First Trust NYSE Arca Biotechnology Index Fund
    -- -- -- --
    XLV
    Health Care Select Sector SPDR Fund
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Google Stock Double by 2030?
Will Google Stock Double by 2030?

If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…

Why Did David Tepper Sell NVIDIA Stock?
Why Did David Tepper Sell NVIDIA Stock?

In Q1, billionaire David Tepper of Appaloosa Management sold nearly…

Why Is Planet Labs Stock Up Today?
Why Is Planet Labs Stock Up Today?

Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 54x

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
NKE alert for Jun 28

Nike [NKE] is up 15.29% over the past day.

Buy
81
KTOS alert for Jun 28

Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.

Sell
44
GDXU alert for Jun 28

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock